FIGO 2023 staging system with/without molecular classification vs. FIGO 2009 in 172 endometrial cancer patients

Ying Han; Ruxue Han; Xingran Jiang; Hong Qu; J. Lu; Hua Li

doi:10.1007/s00404-026-08370-x

April 3, 2026Archives of Gynecology and ObstetricsOpen Access

FIGO 2023 staging system with/without molecular classification vs. FIGO 2009 in 172 endometrial cancer patients

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the comparative effectiveness of the new FIGO 2023 staging system with molecular classification against the FIGO 2009 system in endometrial cancer patients.
Analyzed 172 endometrial cancer patients
Compared FIGO 2023 m staging and FIGO 2009 staging
Assessed risk stratification based on molecular classification
The FIGO 2023 m system showed improved risk stratification compared to FIGO 2009.
Molecular classification was found to be prognostically essential in assessing patient outcomes.

Implication

Compares new molecular classification outcomes in endometrial carcinoma, highlighting the benefits of FIGO 2023.

Abstract

Molecular classification is prognostically essential in endometrial carcinoma. The integrated FIGO 2023 m system appears to enhance risk stratification relative to FIGO 2009 and non-molecular FIGO 2023. Formal comparison of staging systems is needed to confirm this improvement.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Han et al. (2026) studied this question.

synapsesocial.com/papers/69d1fe18a79560c99a0a4a25 https://doi.org/10.1007/s00404-026-08370-x

View Full Paper

Ask AI

Bookmark

Share

FIGO 2023 staging system with/without molecular classification vs. FIGO 2009 in 172 endometrial cancer patients

Key Points

Implication

Abstract

Discussion

Cite This Study

FIGO 2023 staging system with/without molecular classification vs. FIGO 2009 in 172 endometrial cancer patients

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading